Watch TEVJF. Know when insiders buy.
One email the day a filing lands. Free.
TEVJF
TEVA PHARMACEUTICAL INDUSTRIES LTD
38.98
−0.21 −0.54%
USD · close Sep 18
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
19
FLAG · shorts 19
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $45.4BP/E 65.0DIV YIELD —FCF YIELD 2.97%REV TTM $14.1B −15.2%NET INCOME $706MNET DEBT $25.2B52W 33.00 – 39.25SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $4.1B | −0.8% | 52.0% | −$231M | −$576M | −304.3% | -0.49 | $411M | $104M | $307M | Jul 29 |
| Q1 2026 · Mar 31 | $4B | +2.3% | 49.5% | $652M | $369M | +72.4% | 0.31 | −$40M | $168M | −$208M | Apr 29 |
| Q4 2025 · Dec 31 | $1.5B | −64.5% | 177.1% | $300M | $480M | — | 0.41 | $1.2B | $142M | $1B | Feb 3 |
| Q3 2025 · Sep 30 | $4.5B | +3.4% | 51.4% | $882M | $433M | — | 0.37 | $369M | $136M | $233M | Nov 5 |
| Q2 2025 · Jun 30 | $4.2B | +0.3% | 50.3% | $455M | $282M | — | 0.24 | $227M | $96M | $131M | Jul 29 |
| Q1 2025 · Mar 31 | $3.9B | +1.9% | 48.2% | $519M | $214M | — | 0.18 | −$105M | $127M | −$232M | Apr 29 |
| Q4 2024 · Dec 31derived | $4.2B | −5.1% | 50.2% | −$29M | −$217M | −146.9% | -0.19 | $575M | $129M | $446M | Feb 3 |
| Q3 2024 · Sep 30 | $4.3B | +12.5% | 49.6% | −$51M | −$437M | −733.3% | -0.39 | $693M | $148M | $545M | Nov 5 |
| Q2 2024 · Jun 30 | $4.2B | — | 48.6% | −$5M | −$846M | — | -0.75 | $103M | $97M | $6M | Jul 30 |
| Q1 2024 · Mar 31 | $3.8B | — | 46.4% | −$218M | −$139M | — | -0.12 | −$124M | $124M | −$248M | May 7 |
| Q4 2023 · Dec 31derived | $4.5B | — | 54.2% | $756M | $463M | — | 0.41 | $1.2B | $119M | $1.1B | Feb 3 |
| Q3 2023 · Sep 30 | $3.9B | — | 48.1% | $344M | $69M | — | 0.06 | $5M | $149M | −$144M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $17.3B | 51.8% | $2.2B | $1.4B | 8.2% | 1.21 | $1.6B | $501M | $1.1B | — | — |
| FY2024 · to Dec 31 | $16.5B | 48.7% | −$303M | −$1.6B | -9.9% | -1.45 | $1.2B | $498M | $749M | — | — |
| FY2023 · to Dec 31 | $15.8B | 48.2% | $433M | −$559M | -3.5% | -0.50 | $1.4B | $526M | $842M | — | — |
| FY2022 · to Dec 31 | $14.9B | 46.7% | −$2.2B | −$2.4B | -16.4% | -2.20 | $1.6B | $548M | $1B | — | — |
| FY2021 · to Dec 31 | $15.9B | 47.8% | $1.7B | $417M | 2.6% | 0.38 | $798M | $562M | $236M | — | — |
| FY2020 · to Dec 31 | $16.7B | 46.4% | −$3.6B | −$4B | -24.0% | -3.64 | $1.2B | $578M | $638M | — | — |
Every number comes from TEVA PHARMACEUTICAL INDUSTRIES LTD's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.